SmithKline Beckman Corp said it ispursuing a three-point stragey that will achieve a 10 pctannual increase in operating earnings throughout the remainderof the decade.    In 1986, SmithKline earned 521.1 mln dlrs or 6.78 dlrs pershare on revenues of 3.6 billion dlrs.    The company said in its annual report that itsnonpharmaceutical business will play a major role in meetingits earnings growth target, and will in fact grow faster thanits pharmaceutical business.    SmithKline, whose major product is the antiulcer medicationTagamet, said in the report that it intends to improve earningsfrom existing products, expand its product portfolio andoptimize its financial resources.    To bolster its position in the antiulcer market, in whichTagamet has met stiff competition, SmithKline said its strategyto develop an over-the-counter version of Tagamet is bolsteredby two joint ventures, one with &lt;Wellcome PLC>, and one pendingventure in Japan.    SmithKline also said its Allergan Inc eye and skin careproducts division can be a one billion dlr organization in thenext five years that can grow at more than seven to 10 pctannually.    "Nondilutive acquisitions are a real possibility," GavinHerbert, president of the eye and skin care product group saidin the report. In 1986, Allergan had worldwide sales of 433 mlndlrs.    It said its Smith Kline and French Laboratoriespharmaceuticals unit, with 1986 sales of 1.9 billion dlrs, willfile for Food and Drug Administration marketing approval for anumber of cardiovascular agents, including tissue plasminogenactivator, over the next two years.    It also said SK and F's U.S. sales force will be 20 pctlarger in 1987, with more than 1,000 sales personnel.    Smith Kline also said its small clinical laboratory testingunit, with 1986 sales of 373 mln dlrs, performs 24 mln tests ayear, and sees increases in employee drug testing as well as intesting for the AIDS antibody.    Smith Kline said that depending on its share price and thecost of money, it may buy back more shares. In the last threeyears, it has bought back about 25 pct of its shares.    SmithKline begins the year with a new management team,including its new chief operating officer George Ebright. Reuter&#3;